Compounds · Cagrilintide & amylin analogues · continued

Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1 posts 31–32

Compounds › Cagrilintide & amylin analogues cagrisema effect size randomised trial cagrilintide

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

m.restrepoTL2 Moderator22 Jul 2025#31

j.nascimento, post #7: Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer. Go to post

Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.

21 likes in reply to #7 12mo

ThibodeauTL3Regular22 Jul 2025#32

m.restrepo, post #31: Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled. Go to post

Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.

9 likes in reply to #31 12mo

Suggested topics

Topic	Participants	Replies	Views	Activity
Second pass at: Reading a combination trial: attributing effect to components Compounds › Cagrilintide & amylin analogues cagrilintide randomised trial amylin analogues effect size Second pass at: Reading a combination trial: attributing effect to components — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in support of…	+39	43	7.3k	12mo
Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues cagrisema effect size randomised trial Wiki On the subject in the title: Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please…	+2	6	2.4k	7mo
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Compounds › Cagrilintide & amylin analogues effect size cagrilintide cagrisema amylin analogues Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with FLOW ( N Engl…	+48	53	31k	13mo
Why cagrilintide alone is discussed so much less than in combination — does this still hold? Compounds › Cagrilintide & amylin analogues cagrisema randomised trial cagrilintide effect size Solved Under review Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4…	+27	31	1.2k	22h
Reading a combination trial: attributing effect to components Compounds › Cagrilintide & amylin analogues cagrisema amylin analogues effect size cagrilintide Closed On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…		4	19k	11mo

Related topics — sharing the tags cagrisema, effect size, randomised trial

Topic	Participants	Replies	Views	Activity
The C-cell question: rodent findings and their human context — what changed since Compounds › Semaglutide effect size SELECT trial randomised trial type 2 diabetes Closed The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support…	+61	65	1.3k	22mo
Measurement error in a self-reported exposure Evidence › Study critique confounding risk of bias effect size disputed Solved Closed Posting this under the heading it deserves: Measurement error in a self-reported exposure Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it before…	+117	129	45k	5mo
A claim built entirely on a subgroup analysis — what changed since Evidence › Study critique disputed effect size observational data risk of bias Closed On the subject in the title: A claim built entirely on a subgroup analysis — what changed since Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…		2	2k	18mo
Second pass at: Semaglutide and alcohol: what is actually documented Compounds › Semaglutide semaglutide type 2 diabetes effect size randomised trial Closed Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…	+15	19	4.4k	13mo
Retatrutide's phase 2 heart-rate signal and how to think about it Compounds › Retatrutide randomised trial preprint TRIUMPH programme retatrutide On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…	+19	23	20k	7mo